Evidence map›Paper›PMID 36639964›Full record

ReviewMolecular genetics & genomic medicine2023

Rare duplication of the CDC73 gene and atypical hyperparathyroidism-jaw tumor syndrome: A case report and review of the literature.

Guilhaume Garrigues, Marie Batisse-Lignier, Nancy Uhrhammer, Maud Privat, Flora Ponelle-Chachuat, Antony Kelly, Mathilde Gay-Bellile, Sandrine Viala, Yannick Bidet, Yves-Jean Bignon and 1 more

Open access · goldAbstract readReviewCase Reports
In one paragraph

Review in Molecular genetics & genomic medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. A Novel PathogenicJCEM case reports · 2025
    Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Guilhaume GarriguesDépartement d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.
Marie Batisse-LignierUnité de Médecine Nucléaire, Centre Jean Perrin, Clermont-Ferrand, France.
Nancy UhrhammerDépartement d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.
Maud PrivatDépartement d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.
Flora Ponelle-ChachuatDépartement d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.
Antony KellyUnité de Médecine Nucléaire, Centre Jean Perrin, Clermont-Ferrand, France.
Mathilde Gay-BellileDépartement d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.
Sandrine VialaDépartement d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.
Yannick BidetDépartement d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.
Yves-Jean BignonDépartement d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.
Mathias CavailléDépartement d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand, France.ORCID 0000-0002-4079-4891
Inserm · FRCentre Jean Perrin · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyperparathyroidism jaw-tumor syndrome (HPT-JT) is the rarest familial cause of primary hyperparathyroidism, with an incidence <1/1000000, caused by a pathogenic variant in the CDC73 (or HRPT2) gene that encodes parafibromin, a protein involved in many cellular mechanisms. Patients with HPT-JT have a 15-20% of risk of developing parathyroid carcinoma, whereas it accounts for only 1% of all cases of primary hyperparathyroidism. Patients also develop jaw tumors in 30% of cases, kidney abnormalities in 15% of cases, and uterine tumors in 50% of patients. CASE REPORT: Here are report two atypical cases of HPT-JT with variable expressivity in the same family. In front of an isolated primary hyperparathyroidism at 28 years of age of incidental discovery following a weight gain, the propositus benefited a first-line panel by Next-Generation Sequencing of the genes involved in familial hyperparathyroidism: CaSR, CDC73, MEN1, and RET. Genetic testing revealed the presence of a pathogenic germline variation CDC73: c.687_688dup; p.Val230Glufs*28, found only in nine families in the literature and allowing the diagnosis of HPT-JT. Given a history of primary hyperparathyroidism at 52 years and adenomyosis, the patient's mother also underwent a genetic analysis that found her daughter's variation and established her inherited trait.

conclusionIn view of the clinical and genotypic heterogeneity, we confirm the interest of using an extended gene panel for the diagnosis of familial primary hyperparathyroidism. CDC73 variations could be more frequent than described in the literature. The association of primary hyperparathyroidism with uterine involvement could be a new indication for analysis.

Indexed as

FibromaHyperparathyroidism, PrimaryJaw NeoplasmsAdenomaFemaleHumansHyperparathyroidismTumor Suppressor ProteinsCDC73 protein, humanTumor Suppressor ProteinsadenomyosisCDC73HPT-JT syndromerare duplication

Identifiers

PMID36639964
PMCPMC10178793
OpenAlexW4316095895

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.